Free Trial
LON:ETX

e-therapeutics (ETX) Share Price, News & Analysis

e-therapeutics logo
GBX 9 -0.65 (-6.74%)
(As of 05/8/2024)

About e-therapeutics Stock (LON:ETX)

Key Stats

Today's Range
9
10.75
50-Day Range
9
9
52-Week Range
8
24
Volume
2.52 million shs
Average Volume
758,869 shs
Market Capitalization
£52.59 million
P/E Ratio
N/A
Dividend Yield
3.35%
Price Target
N/A
Consensus Rating
N/A

Company Overview

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

Receive ETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ETX Stock News Headlines

Democrats Sold Out the American Dream - Are you ready?
There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters."
RBC Capital Releases a Buy Rating on Edgewise Therapeutics (EWTX)
Aquestive Therapeutics: Progress in Drug Innovation
e-therapeutics Announces Business Updates and Interim Results
See More Headlines

ETX Stock Analysis - Frequently Asked Questions

e-therapeutics' stock was trading at GBX 8.24 at the beginning of the year. Since then, ETX stock has increased by 9.2% and is now trading at GBX 9.
View the best growth stocks for 2024 here
.

e-therapeutics plc (LON:ETX) posted its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.03.

Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that e-therapeutics investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), B&M European Value Retail (BME), Coats Group (COA), Eurasia Mining (EUA), genedrive (GDR) and Greencore Group (GNC).

Company Calendar

Last Earnings
3/17/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Net Income
£-10,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£295,000.00
Cash Flow
GBX 1.77 per share
Book Value
GBX 5 per share

Miscellaneous

Free Float
N/A
Market Cap
£52.59 million
Optionable
Not Optionable
Beta
0.46
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (LON:ETX) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners